CD274 and esophageal cancer: Taking the PD-L1 expression (which is the most studied biomarker now) as an example, in the KEYNOTE 590 trial which evaluated the efficacy of pembrolizumab in esophageal cancer (EC), an improved outcome was obviously seen in the population with PD-L1-positive than that in those with PD-L1-negative (8).